Gosset Kyorin Pharmaceutical General Information
Kyorin Pharmaceutical has over a century of experience in drug discovery and commercialization. The company markets more than160 drugs and diagnostics, with over30 active clinical programs spanning respiratory, otolaryngology, urology, infectious disease, rare/intractable diseases. Notable recent launches include Lyfnua® Tablets for refractory chronic cough and Zonisamide OD tablets for Parkinson’s disease. The company also partners globally on late-stage assets such as efzofitimod for pulmonary sarcoidosis.
Contact Information
Japan
Drug Pipeline
Key Partnerships
aTyr Pharma Inc. – development/commercialization of efzofitimod in Japan for ILD/pulmonary sarcoidosis, ASKA Pharmaceutical – joint development/sales of AKP‑009 for benign prostatic hyperplasia, MSD K.K. – exclusive distribution rights in Japan for Lyfnua® Tablets, Lumen Bioscience – spirulina genetic protein engineering technology, CellGenTech – Fabry disease program, SUSMED Inc. – digital therapeutics collaboration
Kyorin Pharmaceutical Funding
No funding data available